Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis

BACKGROUND: Targeted immunomodulators (TIMs), including biologic disease-modifying antirheumatic drugs (DMARDs) and JAK/STAT inhibitors, are effective therapies for rheumatoid arthritis (RA), but some patients fail to respond or lose response over time. This study estimated the real-world prevalence...

Descripción completa

Detalles Bibliográficos
Autores principales: Strand, Vibeke, Tundia, Namita, Song, Yan, Macaulay, Dendy, Fuldeore, Mahesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397636/
https://www.ncbi.nlm.nih.gov/pubmed/29578852
http://dx.doi.org/10.18553/jmcp.2018.24.4.344

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397636/
https://www.ncbi.nlm.nih.gov/pubmed/29578852
http://dx.doi.org/10.18553/jmcp.2018.24.4.344

Ejemplares similares